Pharmaceutical Investing Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
Pharmaceutical Investing Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy for Stress Urinary Incontinence
Cytori to Expand Scleroderma Focus to Broader Hand Therapy Franchise Under the Habeo™ Cell Therapy Brand
Cytori Announces Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund, LLC
Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American Burn Association Meeting
